Clinical study of Yiqi Xiaozheng Decoctionin treating advanced non-small cell lung cancer(NSCLC)combined with chronic obstructive pulmonary disease(COPD)
马红霞 1李风森1
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 新疆医科大学第四临床医学院呼吸科,乌鲁木齐 830017
折叠
摘要
目的 探讨益气消癥汤治疗晚期非小细胞肺癌(Non-small-cell carcinoma,NSCLC)合并慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)的临床疗效.方法 选择新疆医科大学第四临床医学院2022年3月至2023年1月的130例晚期NSCLC合并COPD患者,按随机数字表法分为对照组和观察组,各65例.对照组接受常规治疗,观察组在对照组常规治疗基础上加用益气消癥汤治疗,比较两组患者治疗前后肺功能水平、治疗效果、免疫功能以及不良反应.结果 治疗3个月后,观察组患者一氧化碳弥散量(Diffusing capacity of the lungs for car-bon monoxide,DLCO)、第一秒用力呼气容积(Forced expiratory volume in one second,FEV1)、FEV1/用力肺活量(Forced vital capacity,FVC)等肺功能指标均较对照组提高(P＜0.05),且总体有效率高于对照组,差异有统计学意义(P＜0.05).观察组的免疫球蛋白含量和T细胞亚群水平均高于对照组(P＜0.05),不良反应发生率低于对照组(P＜0.05).结论 益气消癥汤在改善晚期NSCLC合并COPD患者肺功能、提升治疗效果、增强免疫功能方面优势明显,且不良反应小,临床应用安全可靠.
Abstract
Objective The present study aimed to investigate the clinical efficacy,immunological function,and safety of Yiqi Xiaozheng Decoction in the treatment of advanced non-small cell lung cancer(NSCLC)complicated with chronic obstructive pulmonary disease(COPD).Methods A total of 130 patients with advanced NSCLC and COPD admitted to the hospital between March 2022 and January 2023 were enrolled in this study.Using a simple randomization method,the patients were divided into a control group and a study group,with 65 patients in each group.Both groups received conventional treatment,while the study group received additional oral administration of Yiqi Xiaozheng Decoction.Subsequently,lung function,treatment outcomes,immunological function and adverse reactions were observed and compared between the 2groups.Results After thetreatment,the observed group showed significant improvements(P＜0.05)in lung function indicators,such as the diffusing capacity of the lungs for carbon monoxide(DLCO),forced expiratory volume in one second(FEV1)and the FEV1/forced vital capacity(FVC)ratio,com-pared to the control group.The overall efficacy rate in the observed group was also higher than that of the control group.Furthermore,the observed group exhibited elevated levels of immunoglobulins and T-cell subsets compared to the control group(P＜0.05).Additionally,the occurrence rate of adverse drug reac-tions was lower in the observed group when compared to the control group(P＜0.05).Conclusion Yiqi Xiaozheng Decoction demonstrates significant advantages in improving lung function,enhancing treatment outcomes,and boosting immunological function in patients with advanced NSCLC complicated with COPD,reducing the side effects,and the clinical application is safe and reliable.
维普
万方数据